Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 02, 2015 1:09 PM ET


Company Overview of Agios Pharmaceuticals, Inc.

Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. The company’s product candidates include AG-221, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. Its product candidates also comprise AG-348, an oral small molecule and activator of the pyruvate kinase-R enzyme used for the treatment of patients with PK...

38 Sidney Street

2nd Floor

Cambridge, MA 02139

United States

Founded in 2007

128 Employees



Key Executives for Agios Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 58
Total Annual Compensation: $500.0K
Principal Financial Officer and Senior Vice President of Finance
Age: 44
Total Annual Compensation: $309.0K
Chief Operating Officer
Age: 60
Total Annual Compensation: $375.0K
Chief Medical Officer
Age: 54
Total Annual Compensation: $371.4K
Chief Scientific Officer
Age: 59
Total Annual Compensation: $387.3K
Compensation as of Fiscal Year 2014.

Agios Pharmaceuticals, Inc. Key Developments

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) added to Russell 1000 Index

Agios Pharmaceuticals, Inc. has been added to Russell 1000.

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell 2000 Index

Agios Pharmaceuticals, Inc. will be removed from Russell 2000 Index

Agios Pharmaceuticals, Inc. Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

Agios Pharmaceuticals, Inc. announced dose administration for the first patient in a Phase 1, open-label, dose-escalation and expansion study of single agent AG-881, a small molecule that has shown in preclinical studies to fully penetrate the blood-brain barrier and inhibit isocitrate dehydrogenase-1 (IDH1) and IDH2 mutations in cancer models. The purpose of the Phase 1 multi-center, open-label study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced solid tumors. AG-881 will be administered continuously as a single agent dosed orally in a 28-day cycle. The first portion of the study includes a dose-escalation phase in which cohorts of patients will receive ascending oral doses of AG-881 to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose based on safety and tolerability. The second portion of the study is a dose expansion phase where patients will receive AG-881 to further evaluate the safety, tolerability and clinical activity of the recommended Phase 2 dose. Upcoming Milestones for AG-881: A second dose-escalating and expansion trial, for patients with advanced IDH1 or IDH2 mutant-positive hematologic malignancies whose cancer has progressed on a prior IDH inhibitor therapy, is expected to begin shortly.

Similar Private Companies By Industry

Company Name Region
Microcheck, Inc. United States
California Stem Cell, Inc. United States
Vectoris Pharma LLC United States
Luna Analytics United States
Microbiota Therapeutics, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Agios Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at